Tuuli Ranki

Sanofi (Finland) — Finland

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index1.5kcitations59works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(48), Cancer Research and Treatments(38), CAR-T cell therapy research(37), Viral Infectious Diseases and Gene Expression in Insects(13), Immunotherapy and Immune Responses(8)

Publications58 total

Real-world Evidence of Multiple Myeloma Treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland
Future Oncology·2023· 5 cited
Supplementary Figure 2 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
2023Open Access
Supplementary Table 5 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
2023Open Access
Supplementary Figure 4 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
2023Open Access
Supplementary Table 1 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
2023Open Access
Supplementary Figure 1 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
2023Open Access
Supplementary Table 4 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
2023Open Access
Data from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
2023Open Access
Supplementary Table 3 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
2023Open Access
Supplementary Figure 4 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
2023Open Access
Supplementary Table 3 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
2023Open Access
Supplementary Figure 2 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
2023Open Access
Data from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
2023Open Access
Supplementary Table 5 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
2023Open Access
Supplementary Table 4 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
2023Open Access
Supplementary Table 2 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
2023Open Access
Supplementary Table 2 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
2023Open Access
Supplementary Table 1 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
2023Open Access
Supplementary Figure 3 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
2023Open Access
Supplementary Figure 1 from Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Akseli Hemminki(40), Anna Kanerva(27), Vincenzo Cerullo(26), Lotta Kangasniemi(24), Kaarina Partanen(23), Elina Haavisto(22), Kalevi Kairemo(22), Tuomo Alanko(21), Iulia Diaconu(18), Minna Oksanen(17), Aila Karioja‐Kallio(17), Saila K. Pesonen(17), Liisa Holm(16), Leena Laasonen(16), Sari Pesonen(15), Ulrike Gerdemann(15), Ann M. Leen(15), Satu Kauppinen(15), Tima Joensuu(15), Sari Pesonen(14)